Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04162119
• Other study ID #: HNYY-XYK-01
• Status: Recruiting
• Phase: Phase 2
• Start date: July 7, 2019
• Est. completion date: October 10, 2022

Study information

• Verified date: November 2019
• Source: Chinese PLA General Hospital
• Contact: Quanshun Wang
• Phone: 15692538521
• Email: wqs63[@]sohu.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.

Description:

Previous studies have found that multiple myeloma cells express PD-L1 at a high level. Therefore, the combination of anti-PD-1 or PD-L1 antibodies with CART therapy may further improve the clinical efficacy of CART cell for multiple myeloma.

The investigators screened PD-1 mutant that have high affinity bind with the PD-L1 ligand, and the affinity of the prepared mutant PD-1 Fc fusion protein to bind to PD-L1 reached clinical anti-PD-L1 antibody levels. The investigators prepared BCMA CART cells which secretes the mutant PD-1Fc fusion protein, and the prepared CART cell culture supernatant can well block the binding of PD-L1 to PD-1. Preclinical studies have shown that BCMA CART cells secreting mutant PD-1Fc fusion protein have a superior killing effect on PD-L1 positive multiple myeloma tumor cells to BCMA CART cells which does not express PD-1 fusion protein.

The trial was conducted to explore the safety and efficacy of BCMA-PD1-CART cells in Relapsed/Refractory Multiple Myeloma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: October 10, 2022
• Est. primary completion date: October 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female, aged 14 to 80 years (including 14 and 80 years old).

2. The diagnosis was Refractory/relapsed multiple myeloma.(Meeting 1 of the follow 3 items)

A.Primary treatment patients with no effect after first and second line treatment.

B.Patients who relapsed after complete remission and failed to respond to two kind of therapy.

C.the predicted survival is more than three months.

3. Flow cytometry or immunohistochemistry showed BCMA positive in tumor cells.

4. Patient or his or her legal guardian voluntarily participates in and signs an informed consent form.

5. No serious concomitant disease and major organ function is not serious abnormal.

6. No serious concomitant disease and major organ function is not serious abnormal.

7. the test meets the following indicators:

A.ALT/AST < 2.5 times the upper limit of normal (ULN) and total bilirubin=34.2µmol/L.

B.WBC=2.5×109/L.

C.PT/INR < 1.7 or PT was extended by less than 4 seconds.

Exclusion Criteria:

1. Women who are pregnant or breastfeeding.

2. Transduced positive T lymphocytes < 5% or amplified against CD3/CD28 stimulation < 5 times.

3. Active hepatitis B or hepatitis C, HIV/AIDS infection, any uncontrolled active infection.

4. Patients who are using steroid drugs throughout the body currently.

5. Patients who have received any gene therapy in the past.

6. Patients who are allergy to immunotherapy and related drugs.

7. Patients with heavy heart disease or poorly controlled high blood pressure.

8. Patients who received chemotherapy or radiation 4 weeks before the study began.

9. Patients who are participating in other clinical trials.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Biological:
• BCMA-PD1-CART Cell
This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.

Locations

Country	Name	City	State
China	Hainan Hospital of Chinese PLA General Hospital	Sanya	Hainan

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-related Adverse Events	Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0).	3 years
Secondary	Overall Remission Rate(ORR) of BCMA-PD1-CART cells in Lymphoma	ORR will be assessed from the first CAR-T cell infusion to death or last follow-up	3 years
Secondary	Overall survival(OS) of BCMA-PD1-CART cells in Lymphoma	OS will be assessed from the first CAR-T cell infusion to death or last follow-up	3 years
Secondary	Progress-free survival(PFS) of BCMA-PD1-CART cells in Lymphoma	PFS will be assessed from the first CAR-T cell infusion to death or last follow-up	3 years
Secondary	Rate of BCMA-PD1-CARTcells in peripheral blood cells	In vivo (peripheral blood) rate of BCMA-PD1-CARTcells were determined by means of flow cytometry.	3 years
Secondary	Quantity of BCMA-PD1-CART cells copies in peripheral blood cells.	In vivo (peripheral blood) quantity of BCMA-PD1-CART cells copies copies were determined by means of qPCR.	3 years